Figure 3. Disease-free survival between basiliximab and steroid groups for (A) all recipients (log-rank test, P = 0.913); (B) recipients within Milan criteria (log-rank test, P = 0.022); (C) recipients within UCSF criteria (log-rank test, P = 0.079).